California cannabis flower brand, Flow Kana announced Monday that it s launching a podcast series, Flow Sessions With Jason Silva.
The podcast will welcome celebrity guests and discuss a new point of view at the “intersection of culture, technology, art and states of. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
Share:
Myron Holubiak, president and CEO of
Citius Pharmaceuticals Inc (NASDAQ: CTXR), appeared Thursday at Benzinga s Global Small Cap Conference for an exclusive interview.
The name Citius Pharmaceuticals comes from the Olympic motto Citius, Altius, Fortius, which is Latin for Faster, Higher, Stronger, Holubiak told Benzinga.
The Citius CEO told Benzinga that he and executive chairman Leonard Mazur have collectively invested $26 million in the company.
Mino-Lok: Citius lead asset Mino-Lok is an antibiotic lock solution drug that is used in the treatment of catheter-related bloodstream infections. Mino-Lok is in late stage three clinical studies, Holubiak said.
When a catheter gets infected, the current solution is the costly and painful procedure of removing and replacing it. Complications with the remove and replace procedure include infection, thrombosis, occlusion and mechanical complications, he said, adding that removal and reinsertion causes phys
The Company will showcase an updated Investor Presentation and discuss some of its new technology. Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will present for the Company.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may p